http://orcid.org/0000-0001-6380-3458
References
- Who. Ebola situation report, 30 March 2016. Geneva, Switzerland: World Health Organization; 2016.
- Mire CE, Geisbert TW, Feldmann H, et al. Ebola virus vaccines - reality or fiction? Expert Rev Vaccines. 2016;15(11):1421–1430.
- Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389(10068):505–518.
- Branswell H. As foreign powers approve Ebola vaccines, U.S. drug makers lag in development pipeline. Boston, MA, USA: STAT; 2017.
- Seligman SJ. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine. 2014;32(44):5769–5775.
- Arnemo M, Viksmoen Watle SS, Schoultz KM, et al. Stability of a vesicular stomatitis virus-vectored Ebola vaccine. J Infect Dis. 2016;213(6):930–933.
- Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–1129.
- Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13(4):521–531.
- Mayr A, Stickl H, Müller HK, et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author’s transl). Zentralbl Bakteriol B. 1978;167(5–6):375–390.
- Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord. 2003;3(3):263–271.
- Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997;238(2):198–211.
- Goepfert PA, Elizaga ML, Seaton K, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2014;210(1):99–110.
- Blanchard TJ, Alcami A, Andrea P, et al. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol. 1998;79(Pt 5):1159–1167.
- Domi A, Feldmann F, Basu R, et al. A single dose of modified vaccinia Ankara expressing Ebola virus like particles protects nonhuman primates from lethal Ebola virus challenge. Sci Rep. 2018;8(1):864.
- Schweneker M, Laimbacher AS, Zimmer G, et al. Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles. J Virol. 2017;91:11.
- Lazaro-Frias A, Gomez-Medina S, Sanchez-Sampedro L, et al. Distinct immunogenicity and efficacy of poxvirus-based vaccine candidates against Ebola virus expressing GP and VP40 proteins. J Virol. 2018.
- Rotz LD, Khan AS, Lillibridge SR, et al. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002;8(2):225–230.
- Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26(52):6894–6900.
- Mire CE, Geisbert JB, Versteeg KM, et al. A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred guinea pigs. J Infect Dis. 2015;212(Suppl 2):S384–388.
- Marzi A, Feldmann F, Geisbert TW, et al. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis. 2015;21(2):305–307.